FindTrial
Sign In

Effects of an alpha2 adrenergic agonist and a beta adrenergic antagonist on disturbance of visual function in glaucoma

Effects of an alpha2 adrenergic agonist and a beta adrenergic antagonist on disturbance of visual function in glaucoma

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080222065
Enrollment
60
Registered
2013-04-21
Start date
2013-04-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open-angle glaucoma (POAG)

Interventions

investigational material(s) Generic name etc : brimonidine tartrate INN of investigational material : Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investiga

Sponsors

Tohoku University
Lead Sponsor
Senju Pharmaceutical Co.,LTD.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients had POAG Mean deviation>=-20dB IOP<=21.0mmHg Best corrected visual acuity of 0.5 or better

Exclusion criteria

Exclusion criteria: Any active ocular disease Active retinal disease Ocular surgery within 3 months History of trabeculotomy or trabeculectom

Design outcomes

Primary

MeasureTime frame
retinal sensitivity progression of retinal sensitivity using Humphrey Field Analyzer—

Secondary

MeasureTime frame
intraocular pressure(IOP) Optical coherence tomographic(OCT) finding retinal perfusion change of IOP retinal change using OCT change of retinal perfusion using Laser Speckle Flowgraphy—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026